| 000 | 01142 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250518100503.0 | ||
| 264 | 0 | _c20210527 | |
| 008 | 202105s 0 0 eng d | ||
| 022 | _a1592-8721 | ||
| 024 | 7 |
_a10.3324/haematol.2019.242289 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKloos, Robin Q H | |
| 245 | 0 | 0 |
_aIndividualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. _h[electronic resource] |
| 260 |
_bHaematologica _c05 2021 |
||
| 300 |
_a1254-1261 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAsparaginase |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 700 | 1 | _aMathôt, Ron | |
| 700 | 1 | _aPieters, Rob | |
| 700 | 1 | _avan der Sluis, Inge M | |
| 773 | 0 |
_tHaematologica _gvol. 106 _gno. 5 _gp. 1254-1261 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3324/haematol.2019.242289 _zAvailable from publisher's website |
| 999 |
_c30893839 _d30893839 |
||